Braveheart Bio Earnings Call Transcripts

Fiscal Year 2026

12th Annual Cantor Fitzgerald Global Healthcare Conference

Lead asset BHB-1893 has shown promising phase II results in both obstructive and non-obstructive HCM, with significant biomarker and structural improvements. Global phase III trials are underway, aiming for simplified dosing and broader market adoption, supported by a robust regulatory and financial strategy.

Read full transcript →